Equifax (NYSE:EFX) reported quarterly earnings of $1.98 per share which beat the analyst consensus estimate of $1.71 by 15.79 percent. This is a 23.75 percent increase over earnings of $1.60 per share from the same period last year. The company reported quarterly sales of $1.23 billion which beat the analyst consensus estimate of $1.16 billion by 6.45 percent. This is a 25.64 percent increase over sales of $982.80 million the same period last year.
AnaptysBioFDA Grants Accelerated Approval Of GSK’s JEMPERLI, Which Was Generated By AnaptysBio; Co. Has Earned $20M Milestone Payment As A Result
AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology
